

## Human caspase-1 autoproteolysis is required for ASC-dependent and -independent inflammasome activation

Daniel P. Ball<sup>1#</sup>, Cornelius Y. Taabazuing<sup>1#</sup>, Andrew R. Griswold<sup>2</sup>, Elizabeth L. Orth<sup>3</sup>, Sahana D. Rao<sup>3</sup>, Ilana B. Kotliar<sup>3</sup>, Darren C. Johnson<sup>3</sup> & Daniel A. Bachovchin<sup>1,3,4\*</sup>

### Affiliations:

<sup>1</sup> Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

<sup>2</sup> Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, New York 10065, USA.

<sup>3</sup> Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

<sup>4</sup> Pharmacology Program of the Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

\*Correspondence to Daniel A. Bachovchin: [bachovcd@mskcc.org](mailto:bachovcd@mskcc.org)

#D.P. Ball and C.Y. Taabazuing contributed equally to this paper.

1 **Abstract**

2 Pathogen-related signals induce a number of cytosolic pattern-recognition receptors (PRRs) to  
3 form canonical inflammasomes, which activate pro-caspase-1 and trigger pyroptotic cell death.  
4 All well-studied PRRs oligomerize with the pro-caspase-1-adaptor protein ASC to generate a  
5 single large structure in the cytosol, which induces the autoproteolysis and activation of the pro-  
6 caspase-1 zymogen. However, several PRRs can also directly interact with pro-caspase-1  
7 without ASC, forming much smaller “ASC-independent” inflammasomes. It is currently thought  
8 that pro-caspase-1 autoproteolysis does not occur during, and is not required for, ASC-  
9 independent inflammasome activation. Here, we show that the related human PRRs NLRP1 and  
10 CARD8 exclusively form ASC-dependent and ASC-independent inflammasomes, respectively,  
11 identifying CARD8 as the first PRR that cannot form an ASC-containing signaling platform.  
12 Despite their different structures, we discovered that both the NLRP1 and CARD8 inflammasomes  
13 require pro-caspase-1 autoproteolysis between the small and large catalytic subunits to induce  
14 pyroptosis. Thus, pro-caspase-1 self-cleavage is an obligate regulatory step in the activation of  
15 human canonical inflammasomes.

16

17

18

19

20

21

22

23

24

25

26

## 27 Introduction

28 Caspase-1 is a cysteine protease that induces pyroptotic cell death in response to a  
29 number of pathogen-associated signals (Broz and Dixit, 2016; Lamkanfi and Dixit, 2014).  
30 Typically, an intracellular pattern recognition receptor (PRR) senses a particular microbial  
31 structure or activity and oligomerizes with the adapter protein ASC to form an “ASC focus” in the  
32 cytosol (Broz et al., 2010a; Jones et al., 2010). The pro-caspase-1 zymogen is recruited to this  
33 structure, where it undergoes proximity-induced autoproteolysis to generate a catalytically-active  
34 enzyme. Mature caspase-1 then cleaves and activates the inflammatory cytokines pro-IL-1 $\beta$  and  
35 pro-IL-18 and the pore-forming protein gasdermin D (GSDMD), causing inflammatory cell death  
36 (Kayagaki et al., 2015; Shi et al., 2015). Collectively, the structures that activate pro-caspase-1  
37 are called “canonical inflammasomes”.

38 Two death-fold domains, the pyrin domain (PYD) and the caspase activation and  
39 recruitment domain (CARD), mediate canonical inflammasome assembly (Broz and Dixit, 2016).  
40 ASC is comprised of a PYD and a CARD (**Fig. 1A**), and bridges either a PYD or a CARD of an  
41 activated PRR to the CARD of pro-caspase-1. In mice, all known pro-caspase-1-activating PRRs  
42 form ASC-containing inflammasomes. However, in the absence of ASC, two murine CARD-  
43 containing PRRs, NLRC4 and NLRP1B, can directly recruit and activate pro-caspase-1 through  
44 CARD-CARD interactions (Broz et al., 2010b; Guey et al., 2014; Mariathasan et al., 2004; Poyet  
45 et al., 2001; Van Opdenbosch et al., 2014). ASC-independent inflammasomes induce the  
46 cleavage of GSDMD and trigger lytic cell death, but do not form large foci or efficiently process  
47 pro-caspase-1 and pro-IL-1 $\beta$  (Broz et al., 2010b; He et al., 2015).

48 These observations suggested that pro-caspase-1 autoproteolysis may not be required  
49 for cell death. To explore this possibility, two independent groups reconstituted *Casp1*<sup>-/-</sup> mouse  
50 macrophages (which expressed ASC) with an uncleavable mutant form of mouse pro-caspase-1,  
51 and found that the mutant enzyme still mediated cell death, but did not process pro-IL-1 $\beta$ , in

52 response to various inflammasome stimuli (Broz et al., 2010b; Guey et al., 2014). Another study,  
53 performed after the discovery of GSDMD, showed that the uncleavable mutant pro-caspase-1  
54 was partially defective in processing GSDMD and inducing pyroptosis in ASC-expressing RAW  
55 264.7 cells in response to NLRP3 inflammasome activation (He et al., 2015). Taken together,  
56 these studies indicated that murine ASC-containing inflammasomes can activate pro-caspase-1  
57 to some extent, but that autoproteolysis was required for full catalytic activity. Because ASC-  
58 independent inflammasomes induce little detectable pro-caspase-1 and pro-IL-1 $\beta$  processing, it  
59 has been widely assumed that ASC-independent inflammasomes specifically activate the pro-  
60 protein form of caspase-1 without autoproteolysis. However, the importance of pro-caspase-1  
61 autoproteolysis in mouse ASC-independent inflammasome activation has not been directly  
62 tested, perhaps in part because these structures are not known to form in physiologically-relevant  
63 macrophages that express ASC. Moreover, the requirement of human pro-caspase-1  
64 autoproteolysis in the activation of either ASC-independent or ASC-dependent inflammasomes  
65 has not been evaluated experimentally.

66 DPP8/9 inhibitors activate the related CARD-containing human NLRP1 and CARD8  
67 inflammasomes (**Fig. 1A**), which both have C-terminal ZU5, UPA, and CARD domains (Chui et  
68 al., 2019; Johnson et al., 2018; Okondo et al., 2017; Zhong et al., 2018). The ZU5 domains of  
69 NLRP1 and CARD8 undergo post-translational autoproteolysis (**Fig. 1A**), generating non-  
70 covalently associated, autoinhibited N- and C-terminal polypeptide fragments (D'Oswaldo et al.,  
71 2011; Finger et al., 2012; Frew et al., 2012). The C-terminal UPA-CARD fragments mediate cell  
72 death (Finger et al., 2012; Johnson et al., 2018). CARD8 does not require ASC to activate pro-  
73 caspase-1 (Johnson et al., 2018; Okondo et al., 2017), but it is unknown whether CARD8 can  
74 also form an ASC-containing inflammasome. In contrast, human NLRP1, unlike mouse NLRP1A  
75 and NLRP1B (Masters et al., 2012; Van Opdenbosch et al., 2014), appears to require ASC (Finger  
76 et al., 2012; Zhong et al., 2016; Zhong et al., 2018). Here, we show that CARD8 and NLRP1

77 exclusively form ASC-independent and ASC-dependent inflammasomes, respectively, due to  
78 specific CARD-CARD interactions. These data identify CARD8 as the first pro-caspase-1-  
79 activating PRR that cannot form an ASC focus. Although the CARD8 inflammasome induces little  
80 detectable pro-caspase-1 processing by immunoblotting (Johnson et al., 2018; Okondo et al.,  
81 2017), we found that pro-caspase-1 autoproteolysis was required for activation of both the CARD8  
82 and NLRP1 inflammasomes. Overall, these data demonstrate that autoproteolysis is critical for  
83 the activation of human canonical inflammasomes.

84

## 85 **Results and discussion**

### 86 **NLRP1 is ASC-dependent and CARD8 is ASC-independent**

87 We first wanted to determine the capabilities of human NLRP1 and CARD8 to form ASC-  
88 dependent and ASC-independent inflammasomes. We therefore transfected constructs encoding  
89 NLRP1, CARD8, and/or ASC into HEK 293T cells stably expressing pro-caspase-1 and GSDMD  
90 before treatment with the DPP8/9 inhibitor Val-boroPro (VbP). VbP induced similar levels of  
91 GSDMD cleavage and LDH release in cells expressing CARD8 in the presence or absence of  
92 ASC (**Fig. 1B,C**), confirming that ASC is not required for CARD8-mediated cell death (Johnson  
93 et al., 2018; Okondo et al., 2017). In contrast, NLRP1 required ASC co-expression to mediate  
94 cell death (**Fig. 1B,C**). We should note that the co-expression of NLRP1 and ASC induced some  
95 spontaneous cell death and GSDMD cleavage, but both were increased by VbP. Consistent with  
96 these data, transient transfection of constructs encoding the active UPA-CARD fragment of  
97 NLRP1, but not CARD8, required ASC to induce GSDMD cleavage (**Fig. S1A**). As previously  
98 reported, the PYD of NLRP1 was dispensable for inflammasome activation (**Fig. S1B,C**)  
99 (Chavarria-Smith et al., 2016; Finger et al., 2012).

100 Although these results confirm that CARD8 can directly activate pro-caspase-1 without  
101 ASC bridging, it remained possible that CARD8 could also form an ASC-containing

102 inflammasome, similar to mouse NLRP1B (Van Opdenbosch et al., 2014). We next co-  
103 transfected HEK 293T cells with constructs encoding GFP-tagged ASC and either NLRP1 or  
104 CARD8. These cells were then treated with VbP for 6 h and imaged by fluorescence microscopy  
105 (**Fig. 1D,E**). VbP induced ASC specks in NLRP1, but not CARD8, expressing cells, suggesting  
106 that CARD8 cannot form an ASC-containing inflammasome. Similarly, transfection of the UPA-  
107 CARD of NLRP1, but not CARD8, induced ASC speck formation (**Fig. S1D,E**). To further support  
108 these microscopy results, we co-transfected HEK 293T cells with constructs encoding untagged  
109 ASC and either NLRP1 or CARD8, treated the cells with VbP, and cross-linked lysates with  
110 disuccinimidyl suberate (DSS). As expected, VbP induced ASC oligomerization in cells  
111 expressing NLRP1, but not CARD8 (**Fig. 1F**).

112 We hypothesized that the exclusive formation of ASC-independent and ASC-dependent  
113 inflammasomes by CARD8 and NLRP1, respectively, was due to specific interaction differences  
114 between the CARDS of CARD8 and NLRP1 with the CARDS of ASC and CASP1. To test this  
115 prediction, we incorporated these CARDS into a split luciferase-based NanoBiT assay (Dixon et  
116 al., 2016), fusing Small BiT (SmBiT, an 11 amino acid peptide) to the CARD domains of ASC and  
117 CASP1 and Large BiT (LgBiT, an 18 kDa tag that luminesces only when bound to SmBiT) to the  
118 CARD domains of ASC, CASP1, CARD8, and NLRP1 (**Fig. 2A**). We mixed lysates containing  
119 the indicated fusion proteins, and observed luminescent signals indicating binding between the  
120 ASC<sup>CARD</sup> and itself, CASP1<sup>CARD</sup>, and NLRP1<sup>CARD</sup> (**Fig. 2B**), and between the CASP1<sup>CARD</sup> and itself,  
121 ASC<sup>CARD</sup>, and CARD8<sup>CARD</sup> (**Fig. 2C**). As expected, we did not observe a CASP1<sup>CARD</sup>-NLRP1<sup>CARD</sup>  
122 interaction or an ASC<sup>CARD</sup>-CARD8<sup>CARD</sup> interaction. Overall, these results indicate specific CARD-  
123 CARD interactions govern the formation of the CARD8 ASC-independent inflammasome and the  
124 NLRP1 ASC-dependent inflammasome.

125

126 **Proteasome activity is critical for NLRP1 activation**

127 DPP8/9 inhibition induces the proteasome-mediated degradation of the N-terminal  
128 fragment of mouse NLRP1B and CARD8, releasing the UPA-CARD C-terminal fragment to  
129 activate pro-caspase-1 (Chui et al., 2019; Johnson et al., 2018). Given the differences in the N-  
130 terminal regions of CARD8 and NLRP1 (**Fig. 1A**), we wanted to confirm that VbP activates human  
131 NLRP1 by a similar degradation mechanism. Indeed, autoproteolysis-defective NLRP1 S1213A,  
132 which is unable to release its C-terminal fragment, was severely impaired in VbP-induced ASC  
133 speck formation (**Fig. S2A,B**) and cell death (**Fig. S2C,D**). Moreover, proteasome inhibitors  
134 partially rescued VbP-induced cell death (**Fig. 3A, Fig. S1B**), GSDMD cleavage (**Fig. 3B, Fig.**  
135 **S1C**), and ASC oligomerization (**Fig. 3C**). We speculate that proteasome blockade did not fully  
136 rescue VbP-induced NLRP1 activation because very small amounts of UPA-CARD are needed  
137 to nucleate ASC specks (Sandstrom et al., 2019), and therefore even slight residual proteasome  
138 activity could be sufficient to activate the inflammasome. Consistent with only a small amount of  
139 NLRP1 UPA-CARD being liberated, VbP did not induce obvious NLRP1 protein depletion by  
140 immunoblotting in several experiments (**Fig. 1C, Fig. 3B**). However, we confirmed that VbP does  
141 indeed induce NLRP1 protein depletion by treating NLRP1-expressing HEK 293T cells with VbP  
142 for longer time periods (**Fig. S2E**). It should be noted that these cells do not express pro-caspase-  
143 1, and thus NLRP1 loss here is not due to selective elimination of NLRP1-expressing cells.

144 Germline mutations in the N-terminal fragment of NLRP1 cause several related  
145 inflammatory skin disorders (Zhong et al., 2016; Zhong et al., 2018). We hypothesized that these  
146 mutations destabilized the N-terminal fragment, leading to increased proteasome-mediated N-  
147 terminal degradation. Indeed, we found that the proteasome inhibitor bortezomib reduced  
148 spontaneous inflammasome activation caused by several of these mutations (**Fig. S2F,G**).  
149 Overall, these data indicate that the proteasome mediates both VbP- and mutation-induced  
150 NLRP1 activation.

151

## 152 **The ASC-independent inflammasome requires caspase-1 processing**

153 We next wanted to study the requirements for ASC-independent inflammasome activation  
154 in greater detail. We initially discovered DPP8/9 inhibitor-induced pyroptosis in human THP-1  
155 cells (Okondo et al., 2017), which is mediated by CARD8 (Johnson et al., 2018). We observed  
156 little, if any, caspase-1 and IL-1 $\beta$  processing, and designated this death as “pro-caspase-1  
157 dependent” pyroptosis. However, as described above, we never formally demonstrated that pro-  
158 caspase-1 itself mediates this response. We reasoned that we might observe more caspase-1  
159 processing, if it was occurring, in *GSDMD*<sup>-/-</sup> THP-1 cells, as the cleaved products would not be as  
160 readily released into the supernatant. Indeed, we did observe bands corresponding to the p35  
161 and p20 fragments in these knockout cells (**Fig. 4A-C**), indicating that the CARD8 inflammasome  
162 can, in fact, process pro-caspase-1. It should be noted that VbP induces apoptosis in *GSDMD*<sup>-/-</sup>  
163 THP-1 cells (Taabazuing et al., 2017), and as expected PARP cleavage was observed here.

164 We next wanted to determine if caspase-1 processing was required for cell death.  
165 Analogous to the previously created uncleavable mouse pro-caspase-1 (mCASP1 D6N) (Broz et  
166 al., 2010b), we generated an uncleavable human pro-caspase-1 (CASP1 D5N, **Fig. 4C**) in which  
167 all Asp cleavage sites were mutated to Asn residues (Thornberry et al., 1992). We then created  
168 HEK 293T cell lines stably expressing wild-type (WT), uncleavable (D5N), or catalytically-inactive  
169 (C285A) pro-caspase-1, transiently transfected constructs encoding WT or autoproteolytic-  
170 defective S297A CARD8 into each these cell lines, and treated with VbP. As expected, we  
171 observed robust cell death and GSDMD cleavage in cells with WT pro-caspase-1 and WT  
172 CARD8, but not in cells expressing catalytically-dead CASP1 or autoproteolysis-defective CARD8  
173 (**Fig. 4D**). Interestingly, we also observed a small amount of the p20 cleaved product in the cell  
174 line expressing CASP1 WT. In contrast, we did not observe any cell death or GSDMD cleavage  
175 in cells expressing the uncleavable CASP1 D5N. Consistent with these data, transient  
176 transfection of a plasmid encoding the active UPA-CARD fragment of CARD8 did not induce



177 GSDMD cleavage in cells expressing CASP1 D5N (**Fig. S3A**). Together, these data indicate that  
178 pro-caspase-1 autoproteolysis is required for CARD8 inflammasome activation.

179

#### 180 **Cleavage in the caspase-1 interdomain linker (IDL) is essential for activation**

181 We next wanted to determine which specific pro-caspase-1 cleavage sites were required  
182 for CARD8 inflammasome activation, and to determine if pro-caspase-1 autoproteolysis was also  
183 required for NLRP1 inflammasome activation. Pro-caspase-1 is comprised of three domains, a  
184 CARD, a large subunit (LS, p20), and a small subunit (SS, P10), separated by two linkers (**Fig.**  
185 **4C**). Pro-caspase-1 undergoes proteolytic processing at two sites (D103 and D119) in the CARD  
186 linker (CDL) that separates the CARD and the p20, and three sites (D297, D315, and D316) in  
187 the interdomain linker (IDL) that separates the p20 and the p10 (Boucher et al., 2018; Thornberry  
188 et al., 1992). As IDL cleavage has been associated with higher catalytic activity and CDL cleavage  
189 with termination of activity (Boucher et al., 2018; Broz et al., 2010b), we first tested the 3 putative  
190 cleavage sites in the IDL by generating HEK 293T cells stably expressing CASP1 D297N,  
191 D315N/D316N, and D297N/D315N/D316N (“IDL uncleavable”, or IDL<sup>uncleavable</sup>). We then transfected  
192 plasmids encoding CARD8 or both NLRP1 and ASC into these cell lines and treated with VbP.  
193 We found that VbP induced LDH release and GSDMD cleavage in cells expressing CASP1  
194 D297N and CASP1 D315N/D316N, but not in cells expressing CASP1 IDL<sup>uncleavable</sup> (**Fig. 5**). These data  
195 show that pro-caspase-1 autoproteolysis within the IDL is critical for both ASC-independent and  
196 -dependent inflammasome activation. As predicted by these results, transfection of plasmids  
197 encoding ASC, the UPA-CARD of CARD8, or residues 1-328 of human NLRC4, which contains  
198 a CARD domain that can directly activate human CASP1 (Poyet et al., 2001), failed to induce  
199 death in the cells expressing CASP1 IDL<sup>uncleavable</sup> (**Fig. S3B-D**). In contrast to human CASP1 D5N and  
200 consistent with previous reports (Broz et al., 2010b; Guey et al., 2014), the UPA-CARD of mouse  
201 NLRP1B induced cell death in HEK 293T cells stably expressing the mouse CASP1 D6N protein

202 **(Fig. S3E,F)**. Surprisingly, however, the NLRP1B UPA-CARD also induced the formation of  
203 several lower molecular weight caspase-1 species in the CASP1 D6N-expressing line, indicating  
204 that the mouse CASP1 D6N protein is, in fact, cleavable. These potential additional cleavage  
205 sites and their function in mouse caspase-1 activation warrant future investigations.

206 Replacing CARDs with DmrB domains enables the small-molecule (AP-20187)-induced  
207 dimerization and activation of caspases (Boucher et al., 2018; Ross et al., 2018; Ruhl et al., 2018).  
208 To confirm that IDL cleavage was required for proximity-induced pro-caspase-1 activation, we  
209 cloned DmrB-caspase-1 constructs with the IDL mutations described above **(Fig. S3G)**. We  
210 transiently transfected these constructs into HEK 293T cells, and then treated these cells with the  
211 AP-20187. We observed that the WT DmrB-caspase-1 underwent significant autoproteolysis and  
212 triggered GSDMD cleavage **(Fig. S3H)**. Some pro-caspase-1 autoproteolysis and GSDMD  
213 cleavage were also observed for D297N and the D315N/D316N mutants, but not the IDL<sup>uncl</sup>  
214 mutant. Thus, these data confirm the importance of IDL processing for human caspase-1  
215 activation.

216 Here, we have shown that the related NLRP1 and CARD8 inflammasomes are remarkably  
217 distinct. First, these PRRs have functionally divergent C-terminal UPA-CARD fragments – one  
218 that induces an ASC focus to indirectly activate pro-caspase-1 and one that directly activates pro-  
219 caspase-1. As such, we predict that the physiological outputs of NLRP1 and CARD8 activation  
220 will be different *in vivo*, for example in the kinetics of immune activation or in the type or extent of  
221 cytokine processing. Future investigations are needed to establish the biological purpose of ASC-  
222 independent and ASC-dependent inflammasomes. Second, CARD8 and NLRP1 have entirely  
223 dissimilar N-terminal fragments. Although both are activated by at least one similar signal—the  
224 cellular consequence of DPP8/9 inhibition—we speculate that these N-terminal fragments likely  
225 evolved for different purposes that remain to be elucidated.

226 More generally, we have now demonstrated that human pro-caspase-1 autoproteolysis is  
227 necessary for both ASC-dependent and ASC-independent inflammasome activation.  
228 Interestingly, two recent studies have demonstrated that the related inflammatory caspase-11,  
229 which only forms an ASC-independent inflammasome (termed the “non-canonical”  
230 inflammasome) with often little detectable self-cleavage and no IL-1 $\beta$  processing (Hagar et al.,  
231 2013; Yang et al., 2015), also requires IDL autoproteolysis for activation (Boucher et al., 2018;  
232 Lee et al., 2018). In this way, the ASC-independent caspase-1 canonical inflammasome is  
233 remarkably similar to the non-canonical caspase-11 inflammasome. Collectively, these reports  
234 and our data show that limited proteolysis plays a critical role in the activation of inflammatory  
235 caspases.

236

## 237 **Materials and Methods**

### 238 **Antibodies and reagents**

239 Antibodies used include: GSDMD Rabbit polyclonal Ab (Novus Biologicals, NBP2-33422), human  
240 NLRP1/NALP1 Sheep polyclonal antibody (R&D systems, AF6788), V5 Rabbit polyclonal Ab  
241 (Abcam, Ab91116), FLAG<sup>®</sup> M2 monoclonal Ab (Sigma, F3165), CARD8 N-terminus Rabbit  
242 polyclonal antibody (Abcam, Ab194585), CARD8 C-terminus Rabbit polyclonal Ab (Abcam,  
243 Ab24186), human ASC Sheep polyclonal antibody (R&D systems, AF3805), GAPDH Rabbit  
244 monoclonal Ab (Cell Signaling Tech, 14C10), NLuc (Lg-BiT) polyclonal antibody (courtesy of  
245 Promega), human Caspase-1 p20 Rabbit polyclonal Ab (Cell Signaling Technology, #2225),  
246 PARP Rabbit polyclonal Ab (Cell Signaling Technology, #9542), IRDye 680 RD Streptavidin, (LI-  
247 COR 926-68079), IRDye 800CW anti-rabbit (LICOR, 925-32211), IRDye 800CW anti-mouse (LI-  
248 COR, 925-32210), IRDye 680CW anti-rabbit (LI-COR, 925-68073), IRDye 680CW anti-mouse  
249 (LI-COR, 925-68072). Other reagents used include: Val-boroPro (VbP)(Okondo et al., 2017),  
250 Bortezomib (MilliporeSigma, 504314), MG132 (MilliporeSigma, 474790), Carfilzomib (Cayman

251 Chemical, 17554), B/B Homodimerizer (Takara, 635059, equivalent to AP-20187), disuccinimidyl  
252 suberate (DSS, ThermoFisher Scientific, 21655), FuGENE HD (Promega, E2311).

253

## 254 **Cell Culture**

255 HEK 293T cells and THP-1 cells were purchased from ATCC. HEK 293T cells were grown in  
256 Dulbecco's Modified Eagle's Medium (DMEM) with L-glutamine and 10% fetal bovine serum  
257 (FBS). THP-1 cells were grown in Roswell Park Memorial Institute (RPMI) medium 1640 with  
258 L-glutamine and 10% fetal bovine serum (FBS). All cells were grown at 37 °C in a 5% CO<sub>2</sub>  
259 atmosphere incubator. Cell lines were regularly tested for mycoplasma using the MycoAlert™  
260 Mycoplasma Detection Kit (Lonza). Stable cell lines were generated as described previously  
261 (Johnson et al., 2018).

262

## 263 **Cloning**

264 Plasmids for full-length and truncated CARD8, NLRP1, mouse NLRP1B (allele 1), mouse and  
265 human GSDMD, and mouse and human CASP1 (Johnson et al., 2018; Okondo et al.; Okondo  
266 et al., 2018) were cloned as previously described and shuttled into modified pLEX\_307 vectors  
267 (Addgene) using Gateway technology (Thermo Fisher Scientific). A plasmid encoding NLRC4  
268 was purchased from Origene (RC206757) and cloned into the Gateway system. A pLEX\_307  
269 vector containing RFP was used for controls. Point mutations were generated using the  
270 QuickChange II site-directed mutagenesis kit (Agilent, 200523) following the manufacturer's  
271 instructions. The NLRP1ΔPYD construct starts at Ser93. DNA encoding SmBit and LgBit for  
272 the NanoBiT assay (Promega) were inserted after the attR2 recombination site in a modified  
273 pLEX\_307 vector (immediately after the EcoRV site), and DNA encoding CARD domains were  
274 shuttled into these modified vectors using Gateway technology. DmrBΔCARD caspase-1  
275 chimera constructs were cloned using assembly PCR reactions beginning at Asp92 of  
276 caspase-1.

277

### 278 **Transient transfections**

279 HEK 293T cells were plated in 6-well culture plates at  $5.0 \times 10^5$  cells/well in DMEM. The next day,  
280 the indicated plasmids were mixed with an empty vector to a total of 2.0  $\mu$ g DNA in 125  $\mu$ l in Opti-  
281 MEM and transfected using FuGENE HD (Promega) according to the manufacturer's protocol.  
282 Unless indicated otherwise, 0.02  $\mu$ g CARD8, 0.02  $\mu$ g NLRP1, and 0.005  $\mu$ g ASC were used. The  
283 next day, the cells were treated as described. For microscopy experiments, cells were plated  
284 directly into Nunc Lab-Tek II Chamber slide w/Cover sterile glass slides (Thermo Fisher Scientific,  
285 154534) at  $8.0 \times 10^4$  cells/well and treated with 25  $\mu$ L transfection master mix dropwise.

286

### 287 **LDH cytotoxicity and immunoblotting assays**

288 HEK 293T cells were transiently transfected and inhibitor treated as indicated. THP-1 cells were  
289 plated in 6-well culture plates at  $5.0 \times 10^5$  cells/well and treated with VbP as indicated. 15 min  
290 prior to the conclusion of cell transfection experiments 80  $\mu$ L of a 9% Triton X-100 solution was  
291 added to designated lysis control wells of a 6-well culture plate to completely lyse the cell contents.  
292 Supernatants were analyzed for LDH activity using the Pierce LDH Cytotoxicity Assay Kit (Life  
293 Technologies) and lysates protein content was evaluated by immunoblotting. Cells were washed  
294 2 $\times$  in PBS (pH = 7.4), resuspended in PBS, and lysed by sonication. Protein concentrations were  
295 determined using the DCA Protein Assay kit (Bio-Rad). The samples were separated by SDS-  
296 PAGE, immunoblotted, and visualized using the Odyssey Imaging System (Li-Cor).

297

### 298 **Fluorescence microscopy**

299 Imaging was performed on a Zeiss Axio Observer.Z1 inverted widefield microscope using  
300 40x/0.95NA air objective. Cells were plated on LabTek 8-well chambered cover glass with #1  
301 coverslip. For each chamber, 10 positions were imaged with brightfield, red, and green

302 fluorescence channels as a single time point at the conclusion of the given experiment. Data was  
303 exported as raw .czi files and analyzed using custom macro written in ImageJ/FIJI. Total cell area  
304 was estimated from RFP-positive signal and the number of GFP-ASC specks were quantified  
305 using the “Analyze particles” function following threshold adjustment in the GFP positive images.

306

### 307 **Split luciferase assay**

308 HEK cells were seeded at  $3.0 \times 10^6$  cells in 10 cm dishes and transfected with 3  $\mu$ g of the indicated  
309 DNA construct using FuGENE HD (Promega). 24 h post-transfection, cells were washed with cold  
310 PBS (Corning), harvested by scraping, and pelleted at  $450 \times g$  for 3 min. The pellets were  
311 resuspended in 500  $\mu$ L PBS and lysed by sonication. Lysates were clarified to remove bulk  
312 cellular debris by centrifugation at  $1000 \times g$  for 5 min, and relative expression was normalized by  
313 gel densitometry of immunoblots (ImageJ 1.52n software). NanoBiT assays were carried out in  
314 quadruplicate in white, clear, flat-bottom, 384-well assay plates (Corning, 3765). Equal volume  
315 aliquots of the corresponding SmBiT/LgBiT pairs were combined within each well from normalized  
316 lysates, followed by addition of Nano-Glo Live Cell Reagent, prepared as per manufacturer’s  
317 instructions. Following thermal equilibration, luminescence was read on a Cytation 5 multi-modal  
318 plate reader.

319

### 320 **DSS Cross-linking**

321 HEK 293T cells were treated as indicated before lysates were harvested and pelleted at  $400 \times g$   
322  $4^\circ\text{C}$  for 3 min and washed with cold PBS. Cell pellets were lysed with 200  $\mu$ L 0.5% NP-40 in TBS  
323 for 30 min on ice in 1.75 mL microcentrifuge tubes. The lysates were spun down at  $1,000 g$   $4^\circ\text{C}$   
324 for 10 min to remove bulk cell debris (100  $\mu$ L of supernatant was reserved for immunoblot). The  
325 remaining lysate was placed in the centrifuge for 10 min at  $20,000 \times g$   $4^\circ\text{C}$ . The obtained pellet  
326 was then washed with 100  $\mu$ L CHAPS buffer (50 mM HEPES pH 7.5, 5 mM  $\text{MgCl}_2$ , 0.5 mM EGTA,

327 and 0.1% w/v CHAPS) then resuspended in 48  $\mu$ L CHAPS buffer. 2  $\mu$ L of 250 mM DSS was  
328 added and the samples were agitated at 37 °C on a rotating orbital platform set to 1,000 rpm for  
329 45 min to facilitate protein cross-linking. The samples were then combined with an equal volume  
330 of 2 $\times$  loading dye and heated to 98 °C for 10 min and prepared for immunoblot analysis.

331

### 332 **Data analysis and statistics**

333 Statistical analysis was performed using GraphPad Prism 7.0 software. Statistical significance  
334 was determined using two-sided Students *t*-tests.

335

### 336 **Supplemental material**

337 Fig. S1 shows additional data related to Fig. 1 and Fig. 2, demonstrating that the UPA-CARD of  
338 NLRP1, but not CARD8, interacts with ASC and requires ASC to activate pro-caspase-1. Fig. S2  
339 displays additional data related to Fig. 3, confirming that the proteasome plays an important role  
340 in the activation of human NLRP1. In particular, this figure shows NLRP1 autoproteolysis is  
341 required, that VbP induces NLRP1 protein loss, and spontaneous activation of NLRP1 by  
342 germline mutations is blocked by bortezomib. Fig. S3 shows data related to Fig. 4 and Fig 5.,  
343 confirming that human caspase-1 autoproteolysis within the IDL is required for inflammasome  
344 activation.

345

### 346 **Author Contributions**

347 D.P.B, C.Y.T., A.R.G, S.D.R., and D.C.J. performed experiments. D.P.B, C.Y.T., and D.A.B.  
348 designed experiments, analyzed data, and wrote the paper. I.B.K. and E.L.O. developed and  
349 performed the split luciferase assay.

350

### 351 **Acknowledgements**

352 We thank K. Schroder and P. Broz for sharing DmrB constructs. This work was supported by the  
353 Josie Robertson Foundation (D.A.B.), a Stand Up to Cancer-Innovative Research Grant (Grant  
354 Number SU2C-AACR-IRG11-17 to D.A.B.; Stand Up to Cancer is a program of the Entertainment  
355 Industry Foundation. Research Grants are administered by the American Association for Cancer  
356 Research, the scientific partner of SU2C), the Pew Charitable Trusts (D.A.B. is a Pew-Stewart  
357 Scholar in Cancer Research), the Pershing Square Sohn Cancer Research Alliance (D.A.B.), the  
358 NIH (R01 AI137168 to D.A.B.; T32 GM007739-Andersen to A.R.G; the MSKCC Core Grant P30  
359 CA008748), an Alfred P. Sloan Foundation Research Fellowship (D.A.B.), Gabrielle's Angel  
360 Foundation (D.A.B.), and the American Cancer Society (Postdoctoral Fellowship PF-17-224-01 –  
361 CCG to C.Y.T.).

362

## 363 **References**

- 364 Boucher, D., M. Monteleone, R.C. Coll, K.W. Chen, C.M. Ross, J.L. Teo, G.A. Gomez, C.L. Holley, D.  
365 Bierschenk, K.J. Stacey, A.S. Yap, J.S. Bezbradica, and K. Schroder. 2018. Caspase-1 self-  
366 cleavage is an intrinsic mechanism to terminate inflammasome activity. *J. Exp. Med.*  
367 215:827-840.
- 368 Broz, P., and V.M. Dixit. 2016. Inflammasomes: mechanism of assembly, regulation and signalling.  
369 *Nat. Rev. Immunol.* 16:407-420.
- 370 Broz, P., K. Newton, M. Lamkanfi, S. Mariathasan, V.M. Dixit, and D.M. Monack. 2010a.  
371 Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against  
372 Salmonella. *J. Exp. Med.* 207:1745-1755.
- 373 Broz, P., J. von Moltke, J.W. Jones, R.E. Vance, and D.M. Monack. 2010b. Differential requirement  
374 for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing.  
375 *Cell Host Microbe* 8:471-483.
- 376 Chavarria-Smith, J., P.S. Mitchell, A.M. Ho, M.D. Daugherty, and R.E. Vance. 2016. Functional and  
377 Evolutionary Analyses Identify Proteolysis as a General Mechanism for NLRP1  
378 Inflammasome Activation. *PLoS Pathog.* 12:e1006052.
- 379 Chui, A.J., M.C. Okondo, S.D. Rao, K. Gai, A.R. Griswold, D.C. Johnson, D.P. Ball, C.Y. Taabazuing,  
380 E.L. Orth, B.A. Vitimberga, and D.A. Bachovchin. 2019. N-terminal degradation activates  
381 the NLRP1B inflammasome. *Science* 364:82-85.
- 382 D'Oswaldo, A., C.X. Weichenberger, R.N. Wagner, A. Godzik, J. Wooley, and J.C. Reed. 2011.  
383 CARD8 and NLRP1 undergo autoproteolytic processing through a ZU5-like domain. *PLoS*  
384 *One* 6:e27396.
- 385 Dixon, A.S., M.K. Schwinn, M.P. Hall, K. Zimmerman, P. Otto, T.H. Lubben, B.L. Butler, B.F.  
386 Binkowski, T. Machleidt, T.A. Kirkland, M.G. Wood, C.T. Eggers, L.P. Encell, and K.V. Wood.




- 387 2016. NanoLuc Complementation Reporter Optimized for Accurate Measurement of  
388 Protein Interactions in Cells. *ACS Chem. Biol.* 11:400-408.
- 389 Finger, J.N., J.D. Lich, L.C. Dare, M.N. Cook, K.K. Brown, C. Duraiswami, J. Bertin, and P.J. Gough.  
390 2012. Autolytic proteolysis within the function to find domain (FIIND) is required for  
391 NLRP1 inflammasome activity. *J. Biol. Chem.* 287:25030-25037.
- 392 Frew, B.C., V.R. Joag, and J. Mogridge. 2012. Proteolytic processing of Nlrp1b is required for  
393 inflammasome activity. *PLoS Pathog.* 8:e1002659.
- 394 Guey, B., M. Bodnar, S.N. Manie, A. Tardivel, and V. Petrilli. 2014. Caspase-1 autoproteolysis is  
395 differentially required for NLRP1b and NLRP3 inflammasome function. *Proc. Natl. Acad. Sci. U. S. A.* 111:17254-17259.
- 396
- 397 Hagar, J.A., D.A. Powell, Y. Aachoui, R.K. Ernst, and E.A. Miao. 2013. Cytoplasmic LPS activates  
398 caspase-11: implications in TLR4-independent endotoxic shock. *Science* 341:1250-1253.
- 399 He, W.T., H. Wan, L. Hu, P. Chen, X. Wang, Z. Huang, Z.H. Yang, C.Q. Zhong, and J. Han. 2015.  
400 Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion.  
401 *Cell Res.* 25:1285-1298.
- 402 Johnson, D.C., C.Y. Taabazuing, M.C. Okondo, A.J. Chui, S.D. Rao, F.C. Brown, C. Reed, E. Peguero,  
403 E. de Stanchina, A. Kentsis, and D.A. Bachovchin. 2018. DPP8/DPP9 inhibitor-induced  
404 pyroptosis for treatment of acute myeloid leukemia. *Nat. Med.* 24:1151-1156.
- 405 Jones, J.W., N. Kayagaki, P. Broz, T. Henry, K. Newton, K. O'Rourke, S. Chan, J. Dong, Y. Qu, M.  
406 Roose-Girma, V.M. Dixit, and D.M. Monack. 2010. Absent in melanoma 2 is required for  
407 innate immune recognition of *Francisella tularensis*. *Proc. Natl. Acad. Sci. U. S. A.*  
408 107:9771-9776.
- 409 Kayagaki, N., I.B. Stowe, B.L. Lee, K. O'Rourke, K. Anderson, S. Warming, T. Cuellar, B. Haley, M.  
410 Roose-Girma, Q.T. Phung, P.S. Liu, J.R. Lill, H. Li, J. Wu, S. Kummerfeld, J. Zhang, W.P. Lee,  
411 S.J. Snipas, G.S. Salvesen, L.X. Morris, L. Fitzgerald, Y. Zhang, E.M. Bertram, C.C. Goodnow,  
412 and V.M. Dixit. 2015. Caspase-11 cleaves gasdermin D for non-canonical inflammasome  
413 signalling. *Nature* 526:666-671.
- 414 Lamkanfi, M., and V.M. Dixit. 2014. Mechanisms and functions of inflammasomes. *Cell* 157:1013-  
415 1022.
- 416 Lee, B.L., I.B. Stowe, A. Gupta, O.S. Kornfeld, M. Roose-Girma, K. Anderson, S. Warming, J. Zhang,  
417 W.P. Lee, and N. Kayagaki. 2018. Caspase-11 auto-proteolysis is crucial for noncanonical  
418 inflammasome activation. *J. Exp. Med.* 215:2279-2288.
- 419 Mariathasan, S., K. Newton, D.M. Monack, D. Vucic, D.M. French, W.P. Lee, M. Roose-Girma, S.  
420 Erickson, and V.M. Dixit. 2004. Differential activation of the inflammasome by caspase-1  
421 adaptors ASC and Ipaf. *Nature* 430:213-218.
- 422 Masters, S.L., M. Gerlic, D. Metcalf, S. Preston, M. Pellegrini, J.A. O'Donnell, K. McArthur, T.M.  
423 Baldwin, S. Chevrier, C.J. Nowell, L.H. Cengia, K.J. Henley, J.E. Collinge, D.L. Kastner, L.  
424 Feigenbaum, D.J. Hilton, W.S. Alexander, B.T. Kile, and B.A. Croker. 2012. NLRP1  
425 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. *Immunity*  
426 37:1009-1023.
- 427 Okondo, M.C., D.C. Johnson, R. Sridharan, E.B. Go, A.J. Chui, M.S. Wang, S.E. Poplawski, W. Wu,  
428 Y. Liu, J.H. Lai, D.G. Sanford, M.O. Arciprete, T.R. Golub, W.W. Bachovchin, and D.A.  
429 Bachovchin. 2017. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte  
430 and macrophage pyroptosis. *Nat. Chem. Biol.* 13:46-53.

- 431 Okondo, M.C., S.D. Rao, C.Y. Taabazuig, A.J. Chui, S.E. Poplawski, D.C. Johnson, and D.A.  
432 Bachovchin. 2018. Inhibition of Dpp8/9 Activates the Nlrp1b Inflammasome. *Cell Chem*  
433 *Biol* 25:262-267 e265.
- 434 Poyet, J.L., S.M. Srinivasula, M. Tnani, M. Razmara, T. Fernandes-Alnemri, and E.S. Alnemri. 2001.  
435 Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. *J. Biol.*  
436 *Chem.* 276:28309-28313.
- 437 Ross, C., A.H. Chan, J. Von Pein, D. Boucher, and K. Schroder. 2018. Dimerization and auto-  
438 processing induce caspase-11 protease activation within the non-canonical  
439 inflammasome. *Life Sci Alliance* 1:e201800237.
- 440 Ruhl, S., K. Shkarina, B. Demarco, R. Heilig, J.C. Santos, and P. Broz. 2018. ESCRT-dependent  
441 membrane repair negatively regulates pyroptosis downstream of GSDMD activation.  
442 *Science* 362:956-960.
- 443 Sandstrom, A., P.S. Mitchell, L. Goers, E.W. Mu, C.F. Lesser, and R.E. Vance. 2019. Functional  
444 degradation: A mechanism of NLRP1 inflammasome activation by diverse pathogen  
445 enzymes. *Science* 364:
- 446 Shi, J., Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, Y. Zhuang, T. Cai, F. Wang, and F. Shao. 2015.  
447 Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature*  
448 526:660-665.
- 449 Taabazuig, C.Y., M.C. Okondo, and D.A. Bachovchin. 2017. Pyroptosis and Apoptosis Pathways  
450 Engage in Bidirectional Crosstalk in Monocytes and Macrophages. *Cell Chem Biol* 24:507-  
451 514 e504.
- 452 Thornberry, N.A., H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D. Howard, M.J. Kostura, D.K. Miller,  
453 S.M. Molineaux, J.R. Weidner, J. Aunins, and et al. 1992. A novel heterodimeric cysteine  
454 protease is required for interleukin-1 beta processing in monocytes. *Nature* 356:768-774.
- 455 Van Opendenbosch, N., P. Gurung, L. Vande Walle, A. Fossoul, T.D. Kanneganti, and M. Lamkanfi.  
456 2014. Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-  
457 1 autoproteolysis and speck formation. *Nat Commun* 5:3209.
- 458 Yang, J., Y. Zhao, and F. Shao. 2015. Non-canonical activation of inflammatory caspases by  
459 cytosolic LPS in innate immunity. *Curr. Opin. Immunol.* 32:78-83.
- 460 Zhong, F.L., O. Mamai, L. Sborgi, L. Boussofara, R. Hopkins, K. Robinson, I. Szeverenyi, T. Takeichi,  
461 R. Balaji, A. Lau, H. Tye, K. Roy, C. Bonnard, P.J. Ahl, L.A. Jones, P. Baker, L. Lacina, A.  
462 Otsuka, P.R. Fournie, F. Malecaze, E.B. Lane, M. Akiyama, K. Kabashima, J.E. Connolly, S.L.  
463 Masters, V.J. Soler, S.S. Omar, J.A. McGrath, R. Nedelcu, M. Gribaa, M. Denguezli, A. Saad,  
464 S. Hiller, and B. Reversade. 2016. Germline NLRP1 Mutations Cause Skin Inflammatory  
465 and Cancer Susceptibility Syndromes via Inflammasome Activation. *Cell* 167:187-202  
466 e117.
- 467 Zhong, F.L., K. Robinson, D.E.T. Teo, K.Y. Tan, C. Lim, C.R. Harapas, C.H. Yu, W.H. Xie, R.M. Sobota,  
468 V.B. Au, R. Hopkins, A. D'Oswaldo, J.C. Reed, J.E. Connolly, S.L. Masters, and B. Reversade.  
469 2018. Human DPP9 represses NLRP1 inflammasome and protects against  
470 autoinflammatory diseases via both peptidase activity and FIIND domain binding. *J. Biol.*  
471 *Chem.* 293:18864-18878.
- 472

473

474 **Figures**

475



476

477 **Figure 1. NLRP1 is ASC-dependent and CARD8 is ASC-independent. (A)** Schematic for

478 human NLRP1, CARD8, and ASC protein domain structures. The autoproteolysis sites are

479 indicated. The ZU5-UPA domains together are also referred to as a FIIND. **(B,C)** HEK 293T cells

480 stably expressing CASP1 and GSDMD (HEK 293T<sup>CASP1 + GSDMD</sup>) were transfected with constructs

481 encoding the indicated proteins and treated with DMSO or VbP (10 μM, 6 h). Supernatants were

482 evaluated for LDH release **(B)** and lysates were analyzed by immunoblotting **(C)**. Data are means

483 ± SEM of three biological replicates. \*\*\*  $p < 0.001$  by two-sided Students *t*-test. FL, full-length.  
484 **(D,E)** HEK 293T cells were transfected with constructs encoding GFP-tagged ASC and NLRP1  
485 or CARD8, treated with DMSO or VbP (10 μM, 6 h), and evaluated for ASC speck formation by  
486 fluorescence microscopy. Shown are the mean ± SEM **(D)** and representative images **(E)** from  
487 10 technical replicates from one of two independent experiments. \*\*\*  $p < 0.001$  by two-sided  
488 Students *t*-test. **(F)** HEK 293T cells transiently transfected with constructs encoding the indicated  
489 proteins and treated with DMSO or VbP (10 μM, 6 h). Lysates were harvested, subjected to DSS  
490 crosslinking, and evaluated by immunoblotting.

491

492

493

494

495

496

497

498

499

500


501

502

503

504

505



506

507

508 **Figure 2. Specific CARD-CARD interactions determine ASC-dependent or independent**

509 **inflammasome assembly. (A)** Expression of the indicated LgBiT-tagged CARDs in HEK 293T

510 cells was verified by immunoblotting. **(B,C)** Cell lysates from HEK 293T cells transiently

511 expressing LgBiT-tagged ASC<sup>CARD</sup> **(B)** or LgBiT-tagged CASP1<sup>CARD</sup> **(C)** were mixed with lysates

512 containing SmBiT-tagged CARDs and analyzed for the relative luminescence.

513

514

515

516

517


518

519

520

521

522



523

524 **Figure 3. Proteasome inhibitors block NLRP1 inflammasome activation. (A,B)** HEK

525 293T<sup>CASP1</sup> + GSDMD were transiently transfected with constructs encoding NLRP1 and ASC,

526 pretreated with the indicated proteasome inhibitors (20  $\mu$ M, 30 min), and stimulated with VbP (10

527  $\mu$ M, 6h). Supernatants were evaluated for LDH release (**B**) and lysates were analyzed by

528 immunoblotting (**C**). Data are means  $\pm$  SEM of three biological replicates and representative of

529 two independent experiments. \*  $p < 0.05$ , \*  $p < 0.01$ , \*\*\*  $p < 0.001$  by two-sided Students *t*-test.

530 (**C**) HEK 293T cells transiently transfected with constructs encoding NLRP1 and ASC,

531 preincubated with MG132, carfilzomib, or bortezomib (20  $\mu$ M, 30 min), and treated with DMSO or

532 VbP (10  $\mu$ M, 6 h).

533

534

535

536


537

538

539

540

541



542

543 **Figure 4. Caspase-1 autoproteolysis is required for CARD8 inflammasome activation. (A,B)**

544 Control and *GSDMD*<sup>-/-</sup> THP-1 cells were treated with VbP (10  $\mu$ M, 24 h) before supernatants were  
 545 analyzed for LDH release **(A)** and lysates were evaluated by immunoblotting **(B)**. Data are means  
 546  $\pm$  SEM of three biological replicates. \*\*\*  $p < 0.001$  by two-sided Student's *t*-test. FL, full-length.

547 CL, cleaved. **(C)** Schematic of pro-caspase-1 depicting the CARD domain and large (p20, LS)  
 548 and small (p10, SS) catalytic subunits. Predicted cleavage sites, sizes of potential cleavage  
 549 products, and the catalytic cysteine are indicated. **(D, E)** HEK 293T cells stably expressing  
 550 GSDMD and the indicated pro-caspase-1 constructs were transiently transfected with plasmids  
 551 encoding RFP (mock), CARD8 WT, or autoproteolysis-defective CARD8 S297A (SA) for 24 h  
 552 before addition of VbP (10  $\mu$ M, 6 h). Cell death was assessed by LDH release **(D)** and GSDMD

553 and CASP1 cleavage by immunoblotting (**E**). Data are means  $\pm$  SEM of three biological  
554 replicates. \*\*\*  $p < 0.001$  by two-sided Students *t*-test.

555

556

557

558

559

560

561

562

563

564

565

566


567

568

569

570





571

572

573

574 **Figure 5. Cleavage of the human caspase-1 IDL is required for activation of canonical**

575 **inflammasomes. (A-C)** HEK 293T cells stably expressing GSDMD and the indicated pro-

576 caspase-1 constructs were transiently transfected with plasmids encoding NLRP1 (0.1  $\mu$ g) and

577 ASC (0.01  $\mu$ g) (A,B) or CARD8 (A,C) for 24 h before addition of VbP (10  $\mu$ M, 6 h). Cell death


578 was assessed by LDH release (A) and GSDMD cleavage by immunoblotting (B,C). Data are

579 means  $\pm$  SEM of three biological replicates. \*  $p < 0.05$ , \*\*\*  $p < 0.001$  by two-sided Students  $t$ -

580 test. NS, not significant.

581

582



583

584

585 **Figure S1. The NLRP1 CARD is responsible for inflammasome activation. (A)** HEK 293T<sup>CASP1</sup>

586 + GSDMD cells were transfected with plasmids encoding the UPA-CARD fragments of NLRP1 or

587 CARD8 and ASC as indicated. After 24 h, lysates were evaluated by immunoblotting. **(B,C)** HEK

588 293T<sup>CASP1</sup> + GSDMD were transfected with plasmids encoding full-length NLRP1 or NLRP1 without a

589 pyrin domain (NLRP1ΔPYD) and treated with DMSO or VbP (10 µM, 6 h). Supernatants were

590 evaluated for LDH release **(B)** and lysates were analyzed by immunoblotting **(C)**. Data are means

591 ± SEM of three biological replicates. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  by two-sided Students *t*-test. **(D,E)**

592 HEK 293T cells were transfected with plasmids encoding GFP-tagged ASC and the UPA-CARD

593 fragments of NLRP1 or CARD8, and then evaluated for ASC speck formation by fluorescence

594 microscopy. Shown are the mean  $\pm$  SEM (**D**) and representative images (**E**) from 10 technical  
595 replicates from one of two independent experiments. \*\*\*  $p < 0.001$ , by two-sided Students *t*-test.  
596 NS, not significant.

597

598

599

600

601

602

603

604


605

606

607

608

609



610

611

612 **Figure S2. VbP and germline mutations activate NLRP1 via N-terminal degradation. (A,B)**

613 HEK 293T cells stably expressing CASP1 were transfected with plasmids encoding GFP-tagged

614 ASC and the indicated NLRP1 protein, treated with DMSO or VbP (10 μM, 6 h), and evaluated

615 for ASC speck formation by fluorescence microscopy. Shown are the mean ± SEM **(A)** and

616 representative images **(B)** from 10 technical replicates from one of two independent experiments.

617 \*\*\*  $p < 0.001$ , by two-sided Students  $t$ -test. **(C,D)** HEK 293T<sup>CASP1 + GSDMD</sup> cells were transiently

618 transfected with plasmids encoding autoproteolytic cleavage-deficient NLRP1 S1213A or CARD8

619 S297A with and without ASC, treated with VbP (10 μM, 6 h), and evaluated for LDH release **(C)**

620 and GSDMD cleavage by immunoblotting **(D)**. The data are means ± SEM of three biological

621 replicates. **(E)** HEK 293T cells were transiently transfected with the plasmids encoding CARD8

622 WT (0.1 μg), NLRP1 WT (0.5 μg), or NLRP1 S1213A (0.02 μg) prior to treatment with VbP (10

623  $\mu\text{M}$ , 24 h). Cells were then treated with VbP again (10  $\mu\text{M}$ , 24 h – total of 48 h of treatment)  
624 before lysates were evaluated by immunoblotting. **(F,G)** HEK 293T<sup>CASP1 + GSDMD</sup> cells were  
625 transiently transfected with plasmids encoding the indicated NLRP1 protein and ASC for 24 h  
626 before being treated with bortezomib (20  $\mu\text{M}$ , 6 h). Cell death was evaluated by LDH release **(F)**  
627 and lysates assessed by immunoblotting **(G)**. Data are means  $\pm$  SEM of three biological  
628 replicates. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  by two-sided Students *t*-test.

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643


644

645

646

647

648



649

650 **Figure S3. IDL cleavage is necessary for human pro-caspase-1 activation.** (A) HEK 293T  
 651 cells stably expressing CASP1 WT or CASP1 D5N were transiently transfected with plasmids  
 652 encoding the UPA-CARD fragment of CARD8 (0.1 μg) and GSDMD I104N (0.1 μg). After 24 h,  
 653 lysates were evaluated by immunoblotting. (B-D) HEK 293T cells stably expressing the indicated  
 654 pro-caspase-1 were transiently transfected with the indicated amounts of plasmids encoding ASC  
 655 (B) the UPA-CARD of CARD8 (C), or residues 1-328 of NLRC4 (D). Lysates were evaluated by

656 immunoblotting after 24 h. **(E, F)** HEK 293T cells stably expressing mouse CASP1 WT or CASP1  
657 D6N and mouse GSDMD were transiently transfected with a plasmid encoding the UPA-CARD  
658 fragment of NLRP1B (0.1  $\mu$ g). After 24 h, supernatants were assessed for LDH release **(E)** and  
659 lysates were evaluated by immunoblotting **(F)**. Data are means  $\pm$  SEM of two or three biological  
660 replicates. \*\*\*  $p < 0.001$  by two-sided Students *t*-test. **(G)** Schematic of the DmrB-caspase-1  
661 constructs. Predicted cleavage sites, sizes of potential cleavage products, and the catalytic  
662 cysteine are indicated. **(H)** HEK 293T cells stably expressing GSDMD were transiently transfected  
663 with the indicated DmrB-caspase-1 constructs for 24 h before addition of AP-20187 (500 nM, 1  
664 h). GSDMD and CASP1 cleavage were evaluated by immunoblotting.

665

666

667

668

669

670